Integra LifeSciences Announces Three-Year Contract With Novation to Provide Jarit(R) Sterilization Containers
PLAINSBORO, N.J., April 4, 2011 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has signed a three-year contract with Novation, the leading healthcare supply contracting company, to provide Jarit® sterilization containers to the members of VHA Inc, University HealthSystem Consortium (UHC) and Provista.
"We are pleased that Novation has selected Integra as a contracted supplier of our sterilization containers," said Dan Reuvers, President, Integra Surgical. "By adding containers as a companion to our previously-contracted instruments, we look forward to limiting uncertainty for the members served by Novation by helping them ensure that their instruments are sterilized and cared for in the optimal way."
Integra is a leading provider of surgical instruments used in general surgery, neurosurgery, cardiac surgery and most other surgical modalities, as well as surgical retractor systems and illumination products. Integra's brands include recognized names like Luxtec®, Jarit®, Miltex®, Ruggles™, and Omni-Tract®.
About Integra LifeSciences
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com.
About Novation
Novation is the leading health care supply contracting company for more than 25,000 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances, and 5,500 members of Provista, LLC, representing 28,000 sites. Novation provides alliance members contract and price management and spend management services. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 600 suppliers.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2010 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com